JP2013522303A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522303A5 JP2013522303A5 JP2013500129A JP2013500129A JP2013522303A5 JP 2013522303 A5 JP2013522303 A5 JP 2013522303A5 JP 2013500129 A JP2013500129 A JP 2013500129A JP 2013500129 A JP2013500129 A JP 2013500129A JP 2013522303 A5 JP2013522303 A5 JP 2013522303A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- pulmonary hypertension
- inhalation
- treprostinil
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 19
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical group C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims description 7
- 229960005032 treprostinil Drugs 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000001934 delay Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical group OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 159000000000 sodium salts Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical group COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940014025 tyvaso Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28265910P | 2010-03-15 | 2010-03-15 | |
| US61/282,659 | 2010-03-15 | ||
| PCT/US2011/028390 WO2011115922A1 (en) | 2010-03-15 | 2011-03-14 | Treatment for pulmonary hypertension |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015002312A Division JP2015129129A (ja) | 2010-03-15 | 2015-01-08 | 肺高血圧症のための治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013522303A JP2013522303A (ja) | 2013-06-13 |
| JP2013522303A5 true JP2013522303A5 (cg-RX-API-DMAC10.html) | 2014-05-01 |
| JP5681276B2 JP5681276B2 (ja) | 2015-03-04 |
Family
ID=43858371
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013500129A Active JP5681276B2 (ja) | 2010-03-15 | 2011-03-14 | 肺高血圧症のための治療 |
| JP2015002312A Pending JP2015129129A (ja) | 2010-03-15 | 2015-01-08 | 肺高血圧症のための治療 |
| JP2016052406A Withdrawn JP2016153413A (ja) | 2010-03-15 | 2016-03-16 | 肺高血圧症のための治療 |
| JP2018089769A Pending JP2018135383A (ja) | 2010-03-15 | 2018-05-08 | 肺高血圧症のための治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015002312A Pending JP2015129129A (ja) | 2010-03-15 | 2015-01-08 | 肺高血圧症のための治療 |
| JP2016052406A Withdrawn JP2016153413A (ja) | 2010-03-15 | 2016-03-16 | 肺高血圧症のための治療 |
| JP2018089769A Pending JP2018135383A (ja) | 2010-03-15 | 2018-05-08 | 肺高血圧症のための治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8609728B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP2547341B1 (cg-RX-API-DMAC10.html) |
| JP (4) | JP5681276B2 (cg-RX-API-DMAC10.html) |
| KR (3) | KR101508047B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN102883722B (cg-RX-API-DMAC10.html) |
| CA (2) | CA2892104C (cg-RX-API-DMAC10.html) |
| ES (2) | ES2790859T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2011115922A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2252570B1 (en) | 2007-12-17 | 2017-04-05 | United Therapeutics Corporation | An improved process to prepare treprostinil, the active ingredient in remodulin ® |
| KR101508047B1 (ko) | 2010-03-15 | 2015-04-06 | 유나이티드 세러퓨틱스 코오포레이션 | 폐고혈압의 치료 |
| US8481782B2 (en) | 2010-06-03 | 2013-07-09 | United Therapeutics Corporation | Treprostinil production |
| WO2012118943A1 (en) | 2011-03-02 | 2012-09-07 | United Therapeutics Corporation | Synthesis of intermediate for treprostinil production |
| US9387214B2 (en) | 2012-01-13 | 2016-07-12 | United Therapeutics Corporation | Method of identifying therapies for pulmonary hypertension |
| KR102347340B1 (ko) | 2013-03-14 | 2022-01-06 | 유나이티드 세러퓨틱스 코오포레이션 | 트레프로스티닐의 고체 형태 |
| CN109608326A (zh) | 2013-03-15 | 2019-04-12 | 联合治疗公司 | 曲前列环素的盐 |
| KR102238501B1 (ko) | 2013-03-25 | 2021-04-08 | 유나이티드 세러퓨틱스 코오포레이션 | 링커 티올 및 peg화된 형태를 갖는 프로스타시클린 화합물의 제조 방법 |
| MX382833B (es) | 2013-10-25 | 2025-03-13 | Insmed Inc | Compuestos derivados de prostaciclinas, y el uso de los mismo para el tratamiento de la hipertension pulmonar |
| EP3082428A4 (en) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| EP3164155B1 (en) | 2014-06-13 | 2022-02-09 | United Therapeutics Corporation | Treprostinil formulations |
| JP6224872B1 (ja) | 2014-10-20 | 2017-11-01 | ユナイテッド セラピューティクス コーポレイション | プロスタサイクリン誘導体を生成するための中間体の合成 |
| EP3221291B1 (en) | 2014-11-18 | 2021-03-31 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| US10722558B2 (en) * | 2016-07-15 | 2020-07-28 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| CA3038276A1 (en) | 2016-09-26 | 2018-03-29 | United Therapeutics Corporation | Treprostinil prodrugs |
| EP3554507A1 (en) | 2016-12-14 | 2019-10-23 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
| KR20190030805A (ko) * | 2017-09-14 | 2019-03-25 | 경상대학교산학협력단 | 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법 |
| HU231296B1 (hu) * | 2018-03-09 | 2022-09-28 | Chinoin Zrt | Eljárás treprostinil-dietanol-amin só B polimorf formájának előállítására |
| EA202190552A1 (ru) | 2018-09-18 | 2021-06-18 | Эли Лилли Энд Компани | Эрбуминовая соль трепростинила |
| BR112021021775A2 (pt) | 2019-04-29 | 2022-01-04 | Insmed Inc | Composições de pó seco de pró-fármacos de treprostinil e métodos de uso destas |
| CA3139136A1 (en) | 2019-05-14 | 2020-11-19 | Pharmosa Biopharm Inc. | Pharmaceutical composition of a weak acid drug and methods of administration |
| EP4017588A1 (en) | 2019-08-23 | 2022-06-29 | United Therapeutics Corporation | Treprostinil prodrugs |
| US11826327B2 (en) | 2020-04-17 | 2023-11-28 | United Therapeutics Corporation | Treatment for interstitial lung disease |
| CA3180230A1 (en) | 2020-06-09 | 2021-12-16 | Hitesh Batra | Fumaryl diketopiperidine prodrugs of treprostinil |
| US11826328B2 (en) | 2020-12-14 | 2023-11-28 | United Therapeutics Corporation | Stable treprostinil prodrugs |
| AU2022229367A1 (en) | 2021-03-03 | 2023-09-14 | United Therapeutics Corporation | A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp) |
| AU2023219692A1 (en) | 2022-02-08 | 2024-08-01 | United Therapeutics Corporation | Treprostinil iloprost combination therapy |
| WO2023206444A1 (zh) | 2022-04-29 | 2023-11-02 | 兆科药业（广州）有限公司 | 一种曲前列尼尔软雾吸入剂 |
| KR20250139830A (ko) | 2023-01-19 | 2025-09-23 | 유나이티드 쎄러퓨틱스 코포레이션 | 트레프로스티닐 유사체 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| GB8814438D0 (en) | 1988-06-17 | 1988-07-20 | Wellcome Found | Compounds for use in medicine |
| GB9011588D0 (en) | 1990-05-24 | 1990-07-11 | Wellcome Found | Prostaglandin analogues for use in medicine |
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| CA2312729C (en) | 1997-11-14 | 2006-05-23 | United Therapeutics Corporation | Use of 9-deoxy-2', 9-.alpha.-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease |
| US6521212B1 (en) | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
| US6803386B2 (en) | 2002-01-16 | 2004-10-12 | United Therapeutics Corporation | Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer |
| US7417070B2 (en) | 2003-05-22 | 2008-08-26 | United Therapeutics Corporation | Compounds and methods for delivery of prostacyclin analogs |
| ES2347254T3 (es) | 2003-12-16 | 2010-10-27 | United Therapeutics Corporation | Utilizacion de treprostinil para el tratamiento de las lesiones isquemicas. |
| WO2005058329A1 (en) | 2003-12-16 | 2005-06-30 | United Therapeutics Corporation | Use of treprostinil to improve kidney functions |
| KR101186029B1 (ko) | 2004-04-12 | 2012-09-27 | 유나이티드 쎄러퓨틱스 코포레이션 | 신경병증성 당뇨병성 족부 궤양을 치료하기 위한트레프로스티닐의 용도 |
| ES2707548T3 (es) * | 2006-05-15 | 2019-04-04 | United Therapeutics Corp | Administración de treprostinil utilizando un inhalador de dosis medida |
| WO2008049000A2 (en) * | 2006-10-18 | 2008-04-24 | United Therapeutics Corporation | Combination therapy for pulmonary arterial hypertension |
| CN102648916A (zh) | 2007-02-09 | 2012-08-29 | 联合治疗公司 | 用于间质性肺病和哮喘的曲前列尼治疗 |
| WO2009033039A2 (en) | 2007-09-07 | 2009-03-12 | United Therapeutics Corporation | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
| EP2300408B1 (en) | 2008-05-08 | 2016-04-13 | United Therapeutics Corporation | Process for the preparation of treprostinil monohydrate and its use for storage and shipping |
| US20120177693A1 (en) | 2008-09-25 | 2012-07-12 | Aradigm Corporation | Deep lung pulmonary delivery of treprostinil |
| KR101544246B1 (ko) | 2009-05-07 | 2015-08-12 | 유나이티드 세러퓨틱스 코오포레이션 | 프로스타시클린 유사체의 고체 제제 |
| KR101508047B1 (ko) | 2010-03-15 | 2015-04-06 | 유나이티드 세러퓨틱스 코오포레이션 | 폐고혈압의 치료 |
| WO2012006273A1 (en) | 2010-07-09 | 2012-01-12 | United Therapeutics Corporation | Combination therapies with cox-2 inhibitors and treprostinil |
-
2011
- 2011-03-14 KR KR1020127026242A patent/KR101508047B1/ko active Active
- 2011-03-14 US US13/047,033 patent/US8609728B2/en active Active
- 2011-03-14 EP EP11711190.6A patent/EP2547341B1/en active Active
- 2011-03-14 JP JP2013500129A patent/JP5681276B2/ja active Active
- 2011-03-14 CN CN201180023177.8A patent/CN102883722B/zh active Active
- 2011-03-14 ES ES16182514T patent/ES2790859T3/es active Active
- 2011-03-14 KR KR1020167031528A patent/KR20160132501A/ko not_active Ceased
- 2011-03-14 ES ES11711190.6T patent/ES2611187T3/es active Active
- 2011-03-14 WO PCT/US2011/028390 patent/WO2011115922A1/en not_active Ceased
- 2011-03-14 KR KR1020157004406A patent/KR20150027846A/ko not_active Ceased
- 2011-03-14 CA CA2892104A patent/CA2892104C/en active Active
- 2011-03-14 EP EP16182514.6A patent/EP3108888B1/en active Active
- 2011-03-14 CA CA2791081A patent/CA2791081C/en active Active
-
2013
- 2013-05-22 US US13/899,734 patent/US8969409B2/en active Active
-
2015
- 2015-01-08 JP JP2015002312A patent/JP2015129129A/ja active Pending
-
2016
- 2016-03-16 JP JP2016052406A patent/JP2016153413A/ja not_active Withdrawn
-
2018
- 2018-05-08 JP JP2018089769A patent/JP2018135383A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522303A5 (cg-RX-API-DMAC10.html) | ||
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| JP2006501240A5 (cg-RX-API-DMAC10.html) | ||
| JP6112867B2 (ja) | サキシトキシン誘導体での触覚の喪失の処置 | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| AR065579A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| JP2017533972A5 (cg-RX-API-DMAC10.html) | ||
| JP2013518124A5 (cg-RX-API-DMAC10.html) | ||
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| MY157513A (en) | A water-in-oil type emulsion for treating a disease of the eye | |
| JP2016507500A5 (cg-RX-API-DMAC10.html) | ||
| HK1255584A1 (zh) | 使用阿坎酸及d-环丝胺酸的联合疗法 | |
| WO2011097148A3 (en) | Use of oral heparin preparations to treat urinary tract diseases and conditions | |
| JP2016505050A5 (cg-RX-API-DMAC10.html) | ||
| JP2012525358A5 (cg-RX-API-DMAC10.html) | ||
| PL1732551T3 (pl) | Perheksylina do leczenia przewlekłej niewydolności serca | |
| CN109758452A (zh) | 胺类化合物治疗疼痛的医药用途 | |
| MX2007010886A (es) | Metodos y formulaciones de acarbosa para tratar constipacion cronica. | |
| RU2010154623A (ru) | Производные 1-аминоалкилциклогексана для лечения расстройств сна | |
| JP2009532494A5 (cg-RX-API-DMAC10.html) |